Krishna P Reddy1,2,3, Chung Yin Kong3,4, Emily P Hyle1,3,5, Travis P Baggett3,6,7, Mingshu Huang1,3,8, Robert A Parker1,3,6,8, A David Paltiel9, Elena Losina3,10,11, Milton C Weinstein3,12, Kenneth A Freedberg1,3,5,6,12,13, Rochelle P Walensky1,3,5,6,14. 1. Medical Practice Evaluation Center, Massachusetts General Hospital, Boston. 2. Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston. 3. Harvard Medical School, Boston, Massachusetts. 4. Institute for Technology Assessment, Massachusetts General Hospital, Boston. 5. Division of Infectious Diseases, Massachusetts General Hospital, Boston. 6. Division of General Internal Medicine, Massachusetts General Hospital, Boston. 7. Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston. 8. Biostatistics Center, Massachusetts General Hospital, Boston. 9. Yale School of Public Health, New Haven, Connecticut. 10. Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, Massachusetts. 11. Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts. 12. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 13. Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts. 14. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
Importance: Lung cancer has become a leading cause of death among people living with human immunodeficiency virus (HIV) (PLWH). Over 40% of PLWH in the United States smoke cigarettes; HIV independently increases the risk of lung cancer. Objective: To project cumulative lung cancer mortality by smoking exposure among PLWH in care. Design: Using a validated microsimulation model of HIV, we applied standard demographic data and recent HIV/AIDS epidemiology statistics with specific details on smoking exposure, combining smoking status (current, former, or never) and intensity (heavy, moderate, or light). We stratified reported mortality rates attributable to lung cancer and other non-AIDS-related causes by smoking exposure and accounted for an HIV-conferred independent risk of lung cancer. Lung cancer mortality risk ratios (vs never smokers) for male and female current moderate smokers were 23.6 and 24.2, respectively, and for those who quit smoking at age 40 years were 4.3 and 4.5. In sensitivity analyses, we accounted for nonadherence to antiretroviral therapy (ART) and for a range of HIV-conferred risks of death from lung cancer and from other non-AIDS-related diseases (eg, cardiovascular disease). Main Outcomes and Measures: Cumulative lung cancer mortality by age 80 years (stratified by sex, age at entry to HIV care, and smoking exposure); total expected lung cancer deaths, accounting for nonadherence to ART. Results: Among 40-year-old men with HIV, estimated cumulative lung cancer mortality for heavy, moderate, and light smokers who continued to smoke was 28.9%, 23.0%, and 18.8%, respectively; for those who quit smoking at age 40 years, it was 7.9%, 6.1%, and 4.3%; and for never smokers, it was 1.6%. Among women, the corresponding mortality for current smokers was 27.8%, 20.9%, and 16.6%; for former smokers, it was 7.5%, 5.2%, and 3.7%; and for never smokers, it was 1.2%. ART-adherent individuals who continued to smoke were 6 to 13 times more likely to die from lung cancer than from traditional AIDS-related causes, depending on sex and smoking intensity. Due to greater AIDS-related mortality risks, individuals with incomplete ART adherence had higher overall mortality but lower lung cancer mortality. Applying model projections to the approximately 644 200 PLWH aged 20 to 64 in care in the United States, 59 900 (9.3%) are expected to die from lung cancer if smoking habits do not change. Conclusions and Relevance: Those PLWH who adhere to ART but smoke are substantially more likely to die from lung cancer than from AIDS-related causes.
Importance: Lung cancer has become a leading cause of death among people living with human immunodeficiency virus (HIV) (PLWH). Over 40% of PLWH in the United States smoke cigarettes; HIV independently increases the risk of lung cancer. Objective: To project cumulative lung cancer mortality by smoking exposure among PLWH in care. Design: Using a validated microsimulation model of HIV, we applied standard demographic data and recent HIV/AIDS epidemiology statistics with specific details on smoking exposure, combining smoking status (current, former, or never) and intensity (heavy, moderate, or light). We stratified reported mortality rates attributable to lung cancer and other non-AIDS-related causes by smoking exposure and accounted for an HIV-conferred independent risk of lung cancer. Lung cancer mortality risk ratios (vs never smokers) for male and female current moderate smokers were 23.6 and 24.2, respectively, and for those who quit smoking at age 40 years were 4.3 and 4.5. In sensitivity analyses, we accounted for nonadherence to antiretroviral therapy (ART) and for a range of HIV-conferred risks of death from lung cancer and from other non-AIDS-related diseases (eg, cardiovascular disease). Main Outcomes and Measures: Cumulative lung cancer mortality by age 80 years (stratified by sex, age at entry to HIV care, and smoking exposure); total expected lung cancer deaths, accounting for nonadherence to ART. Results: Among 40-year-old men with HIV, estimated cumulative lung cancer mortality for heavy, moderate, and light smokers who continued to smoke was 28.9%, 23.0%, and 18.8%, respectively; for those who quit smoking at age 40 years, it was 7.9%, 6.1%, and 4.3%; and for never smokers, it was 1.6%. Among women, the corresponding mortality for current smokers was 27.8%, 20.9%, and 16.6%; for former smokers, it was 7.5%, 5.2%, and 3.7%; and for never smokers, it was 1.2%. ART-adherent individuals who continued to smoke were 6 to 13 times more likely to die from lung cancer than from traditional AIDS-related causes, depending on sex and smoking intensity. Due to greater AIDS-related mortality risks, individuals with incomplete ART adherence had higher overall mortality but lower lung cancer mortality. Applying model projections to the approximately 644 200 PLWH aged 20 to 64 in care in the United States, 59 900 (9.3%) are expected to die from lung cancer if smoking habits do not change. Conclusions and Relevance: Those PLWH who adhere to ART but smoke are substantially more likely to die from lung cancer than from AIDS-related causes.
Authors: K A Freedberg; E Losina; M C Weinstein; A D Paltiel; C J Cohen; G R Seage; D E Craven; H Zhang; A D Kimmel; S J Goldie Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: Andrea H Weinberger; Philip H Smith; Allison P Funk; Shayna Rabin; Jonathan Shuter Journal: J Acquir Immune Defic Syndr Date: 2017-04-01 Impact factor: 3.731
Authors: Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: Lancet Date: 2014-07-19 Impact factor: 79.321
Authors: Line D Rasmussen; Marie Helleberg; Margaret T May; Shoaib Afzal; Gitte Kronborg; Carsten S Larsen; Court Pedersen; Jan Gerstoft; Børge G Nordestgaard; Niels Obel Journal: Clin Infect Dis Date: 2015-01-16 Impact factor: 9.079
Authors: Shahida Shahrir; Hilary A Tindle; Kathleen A McGinnis; David A Fiellin; Joseph Goulet; Kathleen M Akgün; Cynthia L Gibert; Maria C Rodriguez-Barradas; Kristina Crothers Journal: Subst Abus Date: 2015-07-13 Impact factor: 3.716
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Boris Julg; Lynda Dee; Jintanat Ananworanich; Dan H Barouch; Katharine Bar; Marina Caskey; Donn J Colby; Liza Dawson; Krista L Dong; Karine Dubé; Joseph Eron; John Frater; Rajesh T Gandhi; Romas Geleziunas; Philip Goulder; George J Hanna; Richard Jefferys; Rowena Johnston; Daniel Kuritzkes; Jonathan Z Li; Udom Likhitwonnawut; Jan van Lunzen; Javier Martinez-Picado; Veronica Miller; Luis J Montaner; Douglas F Nixon; David Palm; Giuseppe Pantaleo; Holly Peay; Deborah Persaud; Jessica Salzwedel; Karl Salzwedel; Timothy Schacker; Virginia Sheikh; Ole S Søgaard; Serena Spudich; Kathryn Stephenson; Jeremy Sugarman; Jeff Taylor; Pablo Tebas; Caroline T Tiemessen; Randall Tressler; Carol D Weiss; Lu Zheng; Merlin L Robb; Nelson L Michael; John W Mellors; Steven G Deeks; Bruce D Walker Journal: Lancet HIV Date: 2019-03-15 Impact factor: 12.767
Authors: Lilli Mann-Jackson; David Choi; Erin L Sutfin; Eunyoung Y Song; Kristie L Foley; Aimee M Wilkin; Caryn G Morse; Nicole F Rojas; Timothy S Oh; Scott D Rhodes Journal: J Cancer Educ Date: 2019-12 Impact factor: 2.037
Authors: Julian A Mitton; Crystal M North; Daniel Muyanja; Samson Okello; Dagmar Vořechovská; Bernard Kakuhikire; Alexander C Tsai; Mark J Siedner Journal: AIDS Care Date: 2018-06-07
Authors: Shivesh Ghura; Robert Gross; Kelly Jordan-Sciutto; Jacob Dubroff; Robert Schnoll; Ronald G Collman; Rebecca L Ashare Journal: J Neuroimmune Pharmacol Date: 2019-12-13 Impact factor: 4.147
Authors: Robert Gross; Kathleen A Brady; Cedric H Bien-Gund; Grace H Choi; Antonios Mashas; Pamela A Shaw; Melissa Miller Journal: AIDS Behav Date: 2021-01